Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity

International Journal of Molecular Medicine

Volumn 17, Issue 3, 2006, Pages 437-447

  Jankun, Jerzy ^a   Specht, Zofia ^a   Szkudlarek, Maria ^a   Greenfield, Robert ^b   Gaikwad, Bhavna ^b   Trifonov, Latchezar ^c   Vaugeois, Jean ^c   Aleem, Ansari M ^a   Basrur, Venkatesha ^a   Selman, Steven H ^a   Zavodszky, Maria I ^d   Skrzypczak Jankun, Ewa ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b American Diagnostica Inc   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d Michigan State University   (United States)

Author keywords

Cancer; Inhibitors; Molecular modeling; PAI 1; Polymerization

Indexed keywords

BIOPOLYMER; FLUORESCENT DYE; LIGAND; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; KINETICS; MASS SPECTROMETRY; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; SEQUENCE ANALYSIS; SPECTROFLUOROMETRY;

AMINO ACID SEQUENCE; BINDING SITES; BIOPOLYMERS; FLUORESCENT DYES; KINETICS; LIGANDS; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN INACTIVATORS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ANALYSIS, PROTEIN; SPECTROMETRY, FLUORESCENCE;

EID: 33644941760     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.3.437     Document Type: Article

References (54)

1. Duffy MJ: The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10: 39-49, 2004.
2. De Bock CE and Wang Y: Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 24: 13-39, 2004.
3. Mazar AP, Henkin J and Goldfarb RH: The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 3: 15-32, 1999.
4. Alfano M, Sidenius N, Blasi F and Poli G: The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection. J Leukoc Biol 74: 750-756, 2003.
5. Dellas C and Loskutoff DJ: Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93: 631-640, 2005.
6. Chorostowska-Wynimko J, Skrzypczak-Jankun E and Jankun J: Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review). Int J Mol Med 13: 759-766, 2004.
7. Agirbasli M: Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 59: 102-106, 2005.
8. Yamamoto K and Saito H: A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 68: 371-385, 1998.
9. Hasenstab D, Lea H and Clowes AW: Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. Arterioscler Thromb Vasc Biol 20: 853-859, 2000.
10. Hornebeck W, Emonard H, Monboisse JC and Bellon G: Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol 12: 231-241, 2002.
11. Stephens RW, Brunner N, Janicke F and Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 52: 99-111, 1998. (Pubitemid 29056088)
12. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
13. Swiercz R, Skrzypczak-Jankun E, Merrell MM, Selman SH and Jankun J: Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep 6: 523-526, 1999.
14. Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH and Jankun J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 8: 463-470, 2001.
15. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH and Jankun J: A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2: 19-28, 2003.
16. Stefansson S, McMahon GA, Petitclerc E and Lawrence DA: Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 9: 1545-1564, 2003.
17. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC and Lawrence DA: Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276: 33964-33968, 2001.
18. Tucker HM, Mottonen J, Goldsmith EJ and Gerard RD: Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol 2: 442-445, 1995.
19. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD and Goldsmith EJ: Structural basis of latency in plasminogen activator inhibitor-1. Nature 355: 270-273, 1992.
20. Berkenpas MB, Lawrence DA and Ginsburg D: Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 14: 2969-2977, 1995.
21. Steinmetzer T: Synthetic urokinase inhibitors as potential antitumor drugs. Drugs 6: 138-146, 2003.
22. Debrock S and Declerck PJ: Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1337: 257-266, 1997.
23. Pedersen KE, Einholm AP, Christensen A, Schack L, Wind T, Kenney JM and Andreasen PA: Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands. Biochem J 372: 747-755, 2003.
24. Komissarov AA, Andreasen PA, Bodker JS, Declerck PJ, Anagli JY and Shore JD: Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. J Biol Chem 280: 1482-1489, 2005.
25. Strandberg L, Karolin J, Johansson LB, Fa M, Aleshkov S and Ny T: Fluorescence studies on plasminogen activator inhibitor 1: reactive centre cysteine mutants remain active after fluorophore attachment. Thromb Res 76: 253-267, 1994.
26. Pabon HJJ: A synthesis of curcumin and related compounds. Rec Trav Chim Pays-Bas 83: 379-385, 1964.
27. Di Santo R, Costi R, Artico M, Ragno R, Greco G, Novellino E, Marchand C and Pommier Y: Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. Farmaco 60: 409-417, 2005.
28. Robinson TP, Hubbard RB, Ehlers TJ, Arbiser JL, Goldsmith DJ and Bowen JP: Synthesis and biological evaluation of aromatic enones related to curcumin. Bioorg Med Chem 13: 4007-4013, 2005.
29. Komissarov AA, Declerck PJ and Shore JD: Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator. J Biol Chem 279: 23007-23013, 2004.
30. Olson ST, Bock PE, Kvassman J, Shore JD, Lawrence DA, Ginsburg D and Bjork I: Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J Biol Chem 270: 30007-30017, 1995.
31. Tunon P and Johansson KE: Yet another improved silver staining method for the detection of proteins in polyacrylamide gels. J Biochem Biophys Methods 9: 171-179, 1984.
32. Basrur V, Yang F, Kushimoto T, Higashimoto Y, Yasumoto K, Valencia J, Muller J, Vieira WD, Watabe H, Shabanowitz J, Hearing VJ, Hunt DF and Appella E: Proteomic analysis of early melanosomes: identification of novel melanosomal proteins. J Proteome Res 2: 69-79, 2003.
33. Schnecke V and Kuhn LA: Virtual screening with solvation and ligand-induced complementarity. Perspect Drug Disc Des 20: 171-190, 2000.
34. Zavodszky MI, Sanschagrin PC, Korde RS and Kuhn LA: Distilling the essential features of a protein surface for improving protein-ligand docking, scoring, and virtual screening. J Comput Aided Mol Des 16: 883-902, 2002.
35. Schnecke V and Kuhn LA: Database screening for HIV protease ligands: the influence of binding-site conformation and representation on ligand selectivity. Proceedings of the Seventh International Conference in Intelligent Systems for Molecular Biology, AAAI Press, 242-251, 1999.
36. Gohlke H, Hendlich M and Klebe G: Knowledge-based scoring function to predict protein-ligand interactions. J Mol Biol 295: 337-356, 2000.
37. Sharp AM, Stein PE, Pannu NS, Carrell RW, Berkenpas MB, Ginsburg D, Lawrence DA and Read RJ: The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure Fold Des 7: 111-118, 1999.
38. Guex N and Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723, 1997.
39. Baker NA, Sept D, Joseph S, Holst MJ and McCammon JA: Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 98: 10037-10041, 2001.
40. Aleshkov SB, Fa M, Karolin J, Strandberg L, Johansson LB, Wilczynska M and Ny T: Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. The distance between P3 and P1′ determined by donor-donor fluorescence energy transfer. J Biol Chem 271: 21231-21238, 1996.
41. Olson ST, Swanson R, Day D, Verhamme I, Kvassman J and Shore JD: Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin. Biochemistry 40: 11742-11756, 2001.
42. Zhou A, Faint R, Charlton P, Dafforn TR, Carrell RW and Lomas DA: Polymerization of plasminogen activator inhibitor-1. J Biol Chem 276: 9115-9122, 2001.
43. Wang H, Pap S and Wiman B: Inactivation of antiplasmin at low pH: evidence for the formation of latent molecules. Thromb Res 114: 301-306, 2004.
44. Wang Q and Shaltiel S: Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases. BMC Biochem 4: 1-15, 2003.
45. Verhamme I, Kvassman JO, Day D, Debrock S, Vleugels N, Declerck PJ and Shore JD: Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem 274: 17511-17517, 1999.
46. Egelund R, Einholm AP, Pedersen KE, Nielsen RW, Christensen A, Deinum J and Andreasen PA: A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity- neutralizing ligands. Ligand-induced serpin polymerization. J Biol Chem 276: 13077-13086, 2001.
47. Gils A, Lu J, Aertgeerts K, Knockaert I and Declerck PJ: Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1. FEBS Lett 415: 192-195, 1997.
48. Naessens D, Gils A, Compernolle G and Declerck PJ: Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. Thromb Haemost 90: 52-58, 2003.
49. Bodker JS, Wind T, Jensen JK, Hansen M, Pedersen KE and Andreasen PA: Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents. Eur J Biochem 270: 1672-1679, 2003.
50. Shore JD, Day DE, Francis-Chmura AM, Verhamme I, Kvassman J, Lawrence DA and Ginsburg D: A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem 270: 5395-5398, 1995.
51. Katsumi TA, Aizawa K, Kuroiwa Y, Saito K, Kurata Y, Ii Y, Okunaka T, Konaka C and Kato H: Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspartyl chlorin E6. Photochem Photobiol 64: 671-675, 1996.
52. Wardell MR, Chang WS, Bruce D, Skinner R, Lesk AM and Carrell RW: Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1. Biochemistry 36: 13133-13142, 1997.
53. Vleugels N, Leys J, Knockaert I and Declerck PJ: Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1. Thromb Haemost 84: 871-875, 2000.
54. Aertgeerts K, De Bondt HL, De Ranter CJ and Declerck PJ: Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat Struct Biol 2: 891-897, 1995.